determining

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

BANTgo and Verofax Team Up to Revolutionize E-waste Collection Through Tokenized Rewards

DUBAI, Oct 24, 2023 - (ACN Newswire) - In an ambitious stride towards environmental sustainability, BANTgo and Verofax have announced a pioneering collaboration to enhance e-waste collection. The groundbreaking partnership seeks to galvanize the masses into responsible recycling by rewarding their endeavors with tokenized incentives. Verofax, was awarded the GITEX Supernova Web3 and Blockchain award, introduces its innovative technology to this eco-initiative. The venture encompasses the deployment of advanced smart bins explicitly designed for e-waste collection. These bins are equipped with a validation system to ensure accurate assessment of the